Validity of the Asthma Control Test Questionnaire Among Smoking Asthmatics

Soler, Xavier; Holbrook, Janet T.; Gerald, Lynn B.; Berry, Cristine E.; Saams, J.N.; Henderson, Robert J.; Sugar, Elizabeth A.; Wise, Robert A.; Ramsdell, Joe

doi:10.1016/j.jaip.2017.05.010

Cited by 10 publications

(11 citation statements)

References 30 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 37 An ACT score of 19 provided an optimum balance of sensitivity (71.3%) and specificity (70.8%) for detecting poorly controlled asthma in non-smokers 37 and a score of 18.6 provided the maximum area under the receiver operator characteristic curve in smokers. 38 The asthma symptom questions in the PATH Study were validated by demonstrating that self-reported asthma symptom severity was associated with functional status, and prevalence of asthma symptoms (wheeze) was similar to the prevalence of symptoms in NHANES (see online supplemental appendix 1 ). People with asthma were also asked whether they used asthma medications in the past 12 months (‘treated asthma’) and what class of medications they regularly used.…”

Section: Methodsmentioning

confidence: 99%

Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2–4

et al. 2023

View full text Add to dashboard Cite

BackgroundResearch on cigarettes and adult asthma offers mixed findings, perhaps due to overlap with chronic obstructive pulmonary disease (COPD) and inadequate adjustment for other smoke exposures. Associations between other tobacco products, including e-cigarettes, and asthma are also understudied.Research questionUsing Population Assessment of Tobacco and Health Study waves 2–4 (2014/2015–2016/2017) data, we assessed the relation between tobacco product use and asthma in persons unlikely to have COPD.Study design and methodsProspective study of 10 267 adults aged 18–39 years without COPD diagnoses. Past-month tobacco use at wave 2 was modelled first as combustible versus non-combustible use and second as specific product categories (former, cigarettes, e-cigarettes, cigars, hookah, smokeless tobacco). Outcomes included lifetime asthma prevalence at wave 2, incidence (waves 3 and 4) and Asthma Control Test score (lower=worse). Multivariable regressions adjusted for predictors of asthma, including other smoke exposures: cigarette pack-years, secondhand smoke and marijuana use. Sensitivity analyses examined findings when persons >39 years and those with both COPD and asthma were added, and when smoke exposure adjustments were removed.ResultsNo product, including cigarettes and e-cigarettes, was associated with prevalence or incidence of asthma. Among people with asthma at wave 2, combustible tobacco (beta=−0.86, 95% CI (−1.32 to –0.39)) and cigarettes (beta=−1.14, 95% CI (−1.66 to –0.62)) were associated with worse asthma control. No tobacco product was associated with asthma control over time. In sensitivity analyses, tobacco use became associated with incident asthma as adults >39 years and those with asthma+COPD were added, and as adjustments for other smoke exposures were omitted.InterpretationAlthough cigarette use was associated with worse asthma control, there were no longitudinal associations between combustible tobacco or e-cigarette use and new onset or worsening asthma in these preliminary analyses. Research on tobacco and asthma should exclude COPD and adjust for smoking history and other smoke exposures.

show abstract

Section: Methodsmentioning

confidence: 99%

Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2–4

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The ACT consists of five questions with five possible answers: 20–25 correlates with well controlled asthma; anything less than 19 represents uncontrolled asthma. The minimally important clinical difference (MCID) is 3 points 14 . Data was collected at 3 (2–4 months), 6 (5–7 months), and >12 months.…”

Section: Methodsmentioning

confidence: 99%

“…The minimally important clinical difference (MCID) is 3 points. 14 Data was collected at 3 (2-4 months), 6 (5-7 months), and >12 months.…”

Section: Introductionmentioning

confidence: 99%

Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)

Garvey

Naimi

Duffy

et al. 2023

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

IntroductionChronic rhinosinusitis with nasal polyposis (CRSwNP) is often treated with endoscopic sinus surgery (ESS), however, patients may require revision surgery due to recurrence. To date, no studies have compared outcomes for combined surgery and biologic therapy for CRSwNP compared to biologic therapy alone.MethodsRetrospective case‐control study of CRSwNP patients who underwent ESS while on dupilumab or mepolizumab (ESS‐biologic cohort), compared to CRSwNP patients on biologic therapy (biologic‐only controls). Cohorts were matched according to indication, aspirin exacerbated respiratory disease (AERD), sinonasal outcome test‐22 (SNOT‐22), and total polyp scores.Results16 patients underwent ESS while on biologic therapy (13 dupilumab and 3 mepolizumab). 16 patients were biologic‐only controls. There were no significant differences between indication, baseline SNOT‐22 scores, polyp scores, and AERD status between cohorts. Patients underwent surgery a median of 33 days after starting biologic therapy. After 12 months of follow up, the total polyp score for the ESS‐biologic cohort decreased from 4.73 to 0.09, compared to biologic‐only controls 5.22 to 3.38 (95% CI of Difference: ‐5.37 to ‐1.38, Cohen's d: 2.40, p = 0.005). In the ESS‐dupilumab sub‐analysis, the ESS‐dupilumab cohort had a significant reduction in polyp burden 4.85 to 0.00 compared to controls 4.88 to 3.50 (95% CI of Difference: ‐5.68 to ‐1.32, Cohen's d: ‐1.69, p = 0.009).ConclusionIn CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared to biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy.This article is protected by copyright. All rights reserved

show abstract

“…Respondents whose asthma was found as controlled or completely controlled were grouped during the analysis. The ACT has been validated on smoker participants [ 13 ]. Therefore, in this research, an ACT-validated Arabic edition was used [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

The Prevalence and Impact of Allergic Rhinitis on Asthma Exacerbations in Asthmatic Adult Patients in the Riyadh Region of Saudi Arabia: A Cross-Sectional Study

Mahfouz¹,

Banjar²,

Assiri³

et al. 2022

Cureus

View full text Add to dashboard Cite

Objectives: Allergic rhinitis (AR) and asthma are highly prevalent conditions known to occur concomitantly. However, observational, cross-sectional studies in Saudi Arabia assessing the frequency and severity of rhinitis in asthmatics adults using questionnaires based on guidelines are unavailable. Therefore, this study attempted to investigate this side and evaluate the role of triggers, symptoms, and family history or history of AR on asthma control levels.Methods: From April 2nd to September 18th, 2021, this observational cross-sectional study was conducted through an online self-administrated questionnaire that was distributed electronically on social media through the SurveyMonkey website (Momentive Inc., Waterford, NY). The study targeted asthmatic adult patients residing in Riyadh city in Saudi Arabia.Results: Overall, 187 questionnaires were analyzed. In this study, the frequency of AR in asthmatic patients was 75.5% (95% CI: 74.87-75.4%). Of those, AR was intermittent mild for 15.0%, intermittent moderate to severe for 43.9%, mild persistent for 2.14%, persistent moderate to severe for 14.4%, and 24.6% of patients were without AR. A significant association was observed between asthma control level and the severity of AR (P < 0.001). Moderate to severe persistent AR was more prevalent in patients with uncontrolled asthma (40.6%) than patients with partially controlled (25%) or controlled asthma (2.7%).Conclusions: This study suggested that AR was related to more severe asthma and more difficulty in controlling asthma. The frequency significantly increased with the severity of asthma.

show abstract

Validity of the Asthma Control Test Questionnaire Among Smoking Asthmatics

Cited by 10 publications

References 30 publications

Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2–4

Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2–4

Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)

The Prevalence and Impact of Allergic Rhinitis on Asthma Exacerbations in Asthmatic Adult Patients in the Riyadh Region of Saudi Arabia: A Cross-Sectional Study

Contact Info

Product

Resources

About